Van't Veer LJ - Search Results

1

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D. Horlings HM, et al. J Clin Oncol. 2008 Sep 20;26(27):4435-41. doi: 10.1200/JCO.2007.14.6969. J Clin Oncol. 2008. PMID: 18802156

2

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L, van Zandwijk N. Rodenhuis S, et al. J Clin Oncol. 1997 Jan;15(1):285-91. doi: 10.1200/JCO.1997.15.1.285. J Clin Oncol. 1997. PMID: 8996154

3

A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.

van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 1997 Aug 15;57(16):3478-85. Cancer Res. 1997. PMID: 9270016

4

Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma.

de Jong D, Richel DJ, Schenkeveld C, Boerrigter L, van 't Veer LJ. de Jong D, et al. Diagn Mol Pathol. 1997 Aug;6(4):244-8. doi: 10.1097/00019606-199708000-00009. Diagn Mol Pathol. 1997. PMID: 9360846

5

Multiple malignancies in a patient with bilateral retinoblastoma.

Ceha HM, Balm AJ, de Jong D, van 't Veer LJ. Ceha HM, et al. J Laryngol Otol. 1998 Feb;112(2):189-92. doi: 10.1017/s0022215100140289. J Laryngol Otol. 1998. PMID: 9578885

6

ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.

Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. Broeks A, et al. Hum Mutat. 1998;12(5):330-7. doi: 10.1002/(SICI)1098-1004(1998)12:5<330::AID-HUMU6>3.0.CO;2-H. Hum Mutat. 1998. PMID: 9792409

7

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods.

Lambrechts AC, van 't Veer LJ, Rodenhuis S. Lambrechts AC, et al. Ann Oncol. 1998 Dec;9(12):1269-76. doi: 10.1023/a:1008445604263. Ann Oncol. 1998. PMID: 9932154 Free article. Review.

8

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. Broeks A, et al. Am J Hum Genet. 2000 Feb;66(2):494-500. doi: 10.1086/302746. Am J Hum Genet. 2000. PMID: 10677309 Free PMC article.

9

Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations.

Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van T Veer LJ. Broeks A, et al. Int J Radiat Biol. 2000 May;76(5):693-8. doi: 10.1080/095530000138367. Int J Radiat Biol. 2000. PMID: 10866292

10

The microarray way to tailored cancer treatment.

Van 't Veer LJ, De Jong D. Van 't Veer LJ, et al. Nat Med. 2002 Jan;8(1):13-4. doi: 10.1038/nm0102-13. Nat Med. 2002. PMID: 11786894 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

394 results

Search Page

Filters